denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: by educational grants from Amgen, Jazz Pharmaceuticals, Servier Pharmaceuticals LLC, and Takeda Oncology
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Leukemia, ALL, Diseases, Therapies, Lymphoid Malignancies
Hematology Disease Topics & Pathways:
Leukemia, ALL, Diseases, Therapies, Lymphoid Malignancies
Friday, December 4, 2020: 11:00 AM-2:00 PM
Chair:
Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center
Disclosures:
Jabbour: Pfizer: Other: Advisory role, Research Funding; Adaptive Biotechnologies: Other: Advisory role, Research Funding; Takeda: Other: Advisory role, Research Funding; Amgen: Other: Advisory role, Research Funding; AbbVie: Other: Advisory role, Research Funding; BMS: Other: Advisory role, Research Funding; Genentech: Other: Advisory role, Research Funding.
Speakers:
Nicola Goekbuget, MD, Head of Study Center Depart of Medicine II, Hematology/Oncology Goethe University Hospital
,
Hagop M. Kantarjian, MD, Professor and Chairman, Department of Leukemia, Samsung Distinguished University Chair in Cancer Medicine, The University of Texas MD Anderson Cancer Center
,
Ching-Hon Pui, MD, Member, St Jude Faculty, Chair, Oncology Department, Coleader, Hematological Malignancies Program, Director, China Region, St Jude Global, American Cancer Society Professor, Fahad Nassar Al-Rashid Chair of Leukemia Research, St Jude Children’s Research H
and
Claire Roddie, PhD, MD, Clinical Lead, CAR-T, University College London Hospitals Senior Lecturer in Haematology, University College London NHS Foundation Trust
Disclosures:
Goekbuget: Servier: Consultancy, Research Funding; Jazz: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Kite: Consultancy; Gilead: Consultancy; Erytech: Consultancy. Kantarjian: Pfizer: Honoraria, Research Funding; Novartis: Research Funding; Jazz Pharma: Research Funding; Actinium: Honoraria, Membership on an entity's Board of Directors or advisory committees; Ariad: Research Funding; Agios: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Takeda: Honoraria; Amgen: Honoraria, Research Funding; BMS: Research Funding; Immunogen: Research Funding; Daiichi-Sankyo: Research Funding; Cyclacel: Research Funding; Astex: Research Funding. Roddie: Celgene: Honoraria; Novartis: Honoraria; Gilead: Honoraria.
Numerous advances have been made in the diagnosis and management of adolescent and young adult (AYA) and adult patients with acute lymphoblastic leukemia (ALL). These include an improved understanding of ALL pathology, including cytogenetic and molecular abnormalities, and the development and incorporation of novel targeted and immune strategies into the field in recent years. Additionally, assessment of measurable/minimal residual disease (MRD) plays an increasing role in prognosis and treatment, and new MRD tests with increasing sensitivity are becoming available.
To help hematologists/oncologists provide the best possible outcomes for their AYA and adult patients with ALL, this Medical Crossfire® will provide an open exchange of ideas and viewpoints. The program features a case-based agenda allowing participants to consider how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. This program will also address approaches to maximize the tolerability of current and emerging therapeutic approaches.
See more of: Satellite Symposia